Medical-Treatment-Enhanced Quality of Life for Women with Fibroids

In two pooled trials, ulipristal acetate was more effective than placebo in improving symptom severity.

Because women with uterine fibroids often prefer noninvasive treatment and may desire future fertility, efforts to find medical alternatives have intensified. Two industry-sponsored placebo-controlled trials of the selective progesterone receptor modulator ulipristal acetate showed that this treatment diminished bleeding and fibroid size (e.g., NEJM Journal Watch Womens Health Mar 2018 and Obstet Gynecol 2018 Mar; 131:431) Now, the investigators have assessed quality of life (QOL) in a pooled analysis of all 589 participants (mean age, 41; 67% black; mean body-mass index, 32 kg/m²) during and after 12 weeks of oral ulipristal (5-mg or 10-mg daily) or placebo.

Significantly greater improvements from baseline in total scores on the Uterine Fib…

Reviewing Author

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Robert W. Rebar, MD

Disclosures

Consultant/Advisory BoardMyovant Sciences, Inc.

Editorial BoardsEndoText; Clinical OB/GYN Alert

Leadership Positions in Professional SocietiesAmerican Society for Reproductive Medicine (Member, Ethics Committee)

Medical-Treatment-Enhanced Quality of Life for Women with Fibroids

Topics

Reviewing Author